Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Change in Account Payables: 2022-2025

Historic Change in Account Payables for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$37.4 million.

  • Axsome Therapeutics' Change in Account Payables fell 1383.93% to -$37.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year decrease of 128.52%. This contributed to the annual value of $31.3 million for FY2024, which is 1410.03% up from last year.
  • As of Q3 2025, Axsome Therapeutics' Change in Account Payables stood at -$37.4 million, which was down 726.59% from $6.0 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Change in Account Payables high stood at $25.8 million for Q4 2022, and its period low was -$37.4 million during Q3 2025.
  • Moreover, its 3-year median value for Change in Account Payables was $7.2 million (2023), whereas its average is $1.4 million.
  • Its Change in Account Payables has fluctuated over the past 5 years, first spiked by 562.50% in 2024, then crashed by 1,383.93% in 2025.
  • Over the past 4 years, Axsome Therapeutics' Change in Account Payables (Quarterly) stood at $25.8 million in 2022, then tumbled by 55.04% to $11.6 million in 2023, then crashed by 33.13% to $7.7 million in 2024, then slumped by 1,383.93% to -$37.4 million in 2025.
  • Its Change in Account Payables was -$37.4 million in Q3 2025, compared to $6.0 million in Q2 2025 and $13.7 million in Q1 2025.